SCHEMBL27213284

SCHEMBL27213284

C[C@@H]1CN(S(=O)(=O)c2cnn(C)c2)CC[C@@H]1Nc1ncc(C(F)(F)F)c(-c2cc(C#N)c(C(C)(C)O)s2)n1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 18/20 0.48
▸ CCNE1 P24864 17/20 0.48
▸ CDK4 P11802 14/20 0.48
▸ CCND1 P24385 14/20 0.48
▸ CCND3 P30281 14/20 0.48
▸ CDK6 Q00534 14/20 0.48
▸ CDK1 P06493 13/20 0.48
▸ CCNB1 P14635 13/20 0.48
▸ CCNT1 O60563 8/20 0.48
▸ CDK7 P50613 8/20 0.48
▸ CDK9 P50750 8/20 0.48
▸ CCNH P51946 8/20 0.48
▸ MNAT1 P51948 8/20 0.48
▸ CCNK O75909 2/20 0.34
▸ CDK12 Q9NYV4 2/20 0.34
▸ CCNA2 P20248 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27213307 0.93 CCNE1 (0.48) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL30906808 0.93 CCNE1 (0.48) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL27213169 0.91 CDK2 (0.50) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL30906770 0.91 CDK2 (0.50) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL30906859 0.91 CCNE1 (0.48) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL27213288 0.91 CCNE1 (0.48) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL27213199 0.90 CCNE1 (0.58) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL30906882 0.90 CCNE1 (0.58) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL30906826 0.89 CCNE1 (0.47) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL27213246 0.89 CCNE1 (0.47) CDK2CCNE1CDK4CCND1CCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150340-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2024-05-09 — — US claimed
WO-2024077216-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2024-04-11 — — WO claimed
US-20240150340-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2024-05-09 — — US disclosed
WO-2024077216-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2024-04-11 — — WO disclosed
WO-2024077216-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2024-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150340-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK1, CDK3 CDK2 4/4885CCNE1 36/4885CDK4 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback